Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas

Title:Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas

Volume: 15 Issue: 6

Author(s): Marc Giry-Laterriere, Andreia V. Pinho, Nils Eling, Lorraine Chantrill and Ilse Rooman

Affiliation:

Keywords: Chemotherapy, Deleted in breast cancer 1, genomic, mutation, pancreas, personalized medicine, Sirtuin 1.

Abstract: Sirtuin 1 is a protein deacetylase that regulates a large number of proteins often functionally implicated in tumor development and progression. Its pleiotropic function has turned SIRT1 into an attractive chemotherapeutic target, underscored by very promising preclinical results with SIRT1 inhibitors in the treatment of chronic myeloid leukemia. Here, we revisit the studies on SIRT1 as an emerging target for therapy in pancreatic cancer, a tumor with dismal outcomes for which currently few therapeutic options are available. We highlight those potential SIRT1 target genes that are commonly affected in pancreatic cancer according to recent genomic analyses.

Cite this article as:

Giry-Laterriere Marc, Pinho V. Andreia, Eling Nils, Chantrill Lorraine and Rooman Ilse, Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas, Current Cancer Drug Targets 2015; 15 (6) . https://dx.doi.org/10.2174/1568009615666150512102957